Insider Transactions in Q4 2020 at Tcr2 Therapeutics Inc. (TCRR)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2020
|
Robert Hofmeister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+13.25%
|
$0
$0.74 P/Share
|
|
Dec 14
2020
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,000
-57.59%
|
$70,000
$35.0 P/Share
|
|
Dec 14
2020
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+36.54%
|
$10,000
$5.88 P/Share
|
|
Nov 17
2020
|
Mayur Ian Somaiya Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,666
-46.0%
|
$109,980
$30.0 P/Share
|
|
Nov 17
2020
|
Mayur Ian Somaiya Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+28.02%
|
$10,000
$5.88 P/Share
|
|
Nov 12
2020
|
Robert Hofmeister Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-20.47%
|
$500,000
$25.1 P/Share
|
|
Nov 12
2020
|
Robert Hofmeister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.99%
|
$0
$0.74 P/Share
|
|
Oct 29
2020
|
Robert Hofmeister Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-33.98%
|
$380,000
$19.1 P/Share
|
|
Oct 29
2020
|
Robert Hofmeister Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+25.36%
|
$0
$0.74 P/Share
|